Kala Pharmaceuticals Inc (OQ:KALA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 100 Beaver St Ste 201
WALTHAM MA 02453-8425
Tel: N/A
Website: kalarx.com
IR: See website
Key People
Mark T. Iwicki
Chairman of the Board, President, Chief Executive Officer
Mary Reumuth
Chief Financial Officer, Treasurer
Todd M. Bazemore
Chief Operating Officer
Hongming Chen
Chief Scientific Officer
Eric L. Trachtenberg
General Counsel, Corporate Secretary
Kim Brazzell
Chief Medical Officer
Business Overview
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company's initial focus is on the treatment of eye diseases. The Company's product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company's product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
Financial Overview
For the three months ended 31 March 2019, Kala Pharmaceuticals Inc revenues increased from $0K to $1.4M. Net loss increased from $11.3M to $25.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $4.3M to $16.4M (expense), Interest expense increase from $367K to $2.1M (expense).
Employees: 130 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $162.37M as of Mar 31, 2019
Annual revenue (TTM): $1.39M as of Mar 31, 2019
EBITDA (TTM): -$76.68M as of Mar 31, 2019
Net annual income (TTM): -$80.83M as of Mar 31, 2019
Free cash flow (TTM): -$74.23M as of Mar 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 33,882,857 as of May 7, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization